CV
A concise web CV. A formal PDF is available on request.
Professional Summary
| Full Name | Zehua (Zack) Wang |
| Current Role | Doctoral Candidate, School of Medicine, University of Auckland |
| Field | Quantitative pharmacology, pharmacometrics, and model-informed dosing |
| Location | Auckland, New Zealand |
| zwan942@aucklanduni.ac.nz | |
| University Profile | profiles.auckland.ac.nz/zack-wang |
| Languages | English; Chinese (Mandarin); Chinese (Cantonese) |
Education
-
2025-Present Doctoral Candidate in Pharmacology and Clinical Pharmacology
University of Auckland, Faculty of Medical and Health Sciences, School of Medicine - Doctoral research: Advancing the Evidence for Model-Based Dosing in the Clinical Setting.
- Evaluates how model-informed dosing tools such as NextDose can support dosing, sampling, and implementation decisions for high-risk medicines.
- Uses clinical trial simulation, population PK/PD modelling, optimal design, and retrospective assessment of model-based dosing frameworks.
-
2022-2025 Master of Science
China Pharmaceutical University, Nanjing, China - Research in pharmacokinetics, PBPK/PD modelling, drug disposition, and translational pharmacology.
- First author of a PBPK-PD model of topoisomerase inhibitor antibody-drug conjugates published in European Journal of Pharmaceutical Sciences.
-
2018-2022 Bachelor of Engineering
Shandong First Medical University, Jinan, China - Training in pharmaceutical engineering, laboratory methods, formulation-related research, and data analysis.
Selected Research
-
2025-Present Model-based dosing evidence in routine clinical care
University of Auckland - Uses clinical trial simulation and population PK/PD modelling to evaluate how model-informed dosing tools may support dosing, sampling, and implementation decisions for high-risk medicines.
- Keeps assumptions, uncertainty, and limits of model-based inference explicit for clinical, regulatory, and health-system readers.
-
2026 AUC-guided vancomycin clinical trial simulation
University of Auckland - Built an R/NONMEM/Wings for NONMEM workflow comparing Bayesian target-concentration intervention with empirical trough-guided dosing under clinically realistic execution events.
- The N=200 reproduction run tracked AUC24 target-window attainment, dosing delays, missed or cancelled doses, missing samples, and dropout.
- Reports simulation findings as design evidence, not as direct clinical recommendations.
-
2022-2025 Translational PBPK/PD and drug-disposition modelling
China Pharmaceutical University - Developed and contributed to PBPK, PBPK/PD, and transporter-mediated drug-disposition analyses across antibody-drug conjugates, neuroprotective agents, and liver-injury models.
Selected Publications
- Wang Z, Zhu J, Sang L, Tang L, Zhang S, Tan Y, Zhao Y, Hao K. PBPK-PD model for predicting pharmacokinetics, tumor growth inhibition, and toxicity risks of topoisomerase inhibitor ADCs in mice and humans. European Journal of Pharmaceutical Sciences. 2025;213:107234. doi:10.1016/j.ejps.2025.107234.
- Zhu X, Kong W, Wang Z, Liu X, Liu L. Prediction of SPT-07A Pharmacokinetics in Rats, Dogs, and Humans Using a Physiologically-Based Pharmacokinetic Model and In Vitro Data. Pharmaceutics. 2024;16(12):1596. doi:10.3390/pharmaceutics16121596.
- Zhi H, Zhongyan Wang, Zhu X, Wu W, Yang L, Dai Y, Zehua Wang, Jiang L, et al. Chronic liver injury decreases levels of cerebral carnitine and acetylcarnitine in rats partly due to the downregulation of organic cation transporters OCT1/2 and OCTN2 at the blood-brain barrier. Drug Metabolism and Disposition. 2025;53(5):100072. doi:10.1016/j.dmd.2025.100072.
- Zhi H, Dai Y, Su L, Yang L, Wu W, Zehua Wang, Zhu X, Liu L. Thioacetamide-Induced Acute Liver Injury Increases Metformin Plasma Exposure by Downregulating Renal OCT2 and MATE1 Expression and Function. Biomedicines. 2023;11(12):3314. doi:10.3390/biomedicines11123314.
Technical Capabilities
-
Pharmacometrics and clinical pharmacology
- Population PK and PK/PD modelling; exposure-response and disease-progression modelling.
- Clinical trial simulation, model-informed dosing, optimal sampling, and scenario analysis.
- Model evaluation with diagnostic plots, simulation-based checks, sensitivity analyses, and traceable assumptions.
-
Software and reproducible workflows
- R, NONMEM, Wings for NONMEM, Monolix, Phoenix WinNonlin, PK-Sim, and Berkeley Madonna.
- R Markdown or Quarto-style reporting, Git-based version control, and automated tables and figures.
-
Biomedical and translational methods
- PBPK/PD modelling, in vitro-in vivo extrapolation, transporter-mediated disposition, HPLC-MS, qPCR, and Western blotting.
Honours and Service
-
2026 - Judging and Prizing Committee Co-Lead, HealtheX 2026, Faculty of Medical and Health Sciences.
-
2025 - Outstanding Graduate, China Pharmaceutical University.
-
2024 - Exploring the World Scholarship for International Research.
- Excellent Poster, 14th National Drug Metabolism Conference.
-
2022 - Outstanding Graduate, Shandong First Medical University.
Research Interests
-
Model-informed dosing
- Evidence for dosing and sampling decisions in routine care.
- Bayesian dose individualisation and implementation of model-based dosing tools.
-
Quantitative clinical pharmacology
- Population PK/PD, exposure-response, disease progression, and clinical trial simulation.
- Transparent reporting for clinical, regulatory, and policy-facing audiences.
-
Translational pharmacology
- PBPK/PD modelling, cross-species extrapolation, and transporter-mediated drug disposition.